SLGL vs. DTIL, CNTB, RAPT, OMGA, ENTX, IMNN, JATT, GRTS, VNRX, and ALRN
Should you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include Precision BioSciences (DTIL), Connect Biopharma (CNTB), RAPT Therapeutics (RAPT), Omega Therapeutics (OMGA), Entera Bio (ENTX), Imunon (IMNN), JATT Acquisition (JATT), Gritstone bio (GRTS), VolitionRx (VNRX), and Aileron Therapeutics (ALRN). These companies are all part of the "pharmaceutical products" industry.
Precision BioSciences (NASDAQ:DTIL) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment.
Precision BioSciences presently has a consensus price target of $39.50, suggesting a potential upside of 285.37%. Sol-Gel Technologies has a consensus price target of $5.00, suggesting a potential upside of 706.45%. Given Sol-Gel Technologies' higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than Precision BioSciences.
Precision BioSciences has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500.
38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 4.0% of Precision BioSciences shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Sol-Gel Technologies has lower revenue, but higher earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Sol-Gel Technologies, indicating that it is currently the more affordable of the two stocks.
Sol-Gel Technologies received 59 more outperform votes than Precision BioSciences when rated by MarketBeat users. However, 67.67% of users gave Precision BioSciences an outperform vote while only 63.40% of users gave Sol-Gel Technologies an outperform vote.
Precision BioSciences has a net margin of 19.36% compared to Sol-Gel Technologies' net margin of -227.40%. Precision BioSciences' return on equity of -7.64% beat Sol-Gel Technologies' return on equity.
In the previous week, Precision BioSciences' average media sentiment score of 0.00 equaled Sol-Gel Technologies'average media sentiment score.
Summary
Precision BioSciences and Sol-Gel Technologies tied by winning 7 of the 14 factors compared between the two stocks.
Get Sol-Gel Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sol-Gel Technologies Competitors List
Related Companies and Tools
Free SLGL Stock Alerts